Regulatory update
FDA guidance on unapproved retatrutide: what the current statement says
The FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Read the FDA statementResearch news and updates
News
Source-led articles, research summaries and dated updates.
Peer-reviewed analysis
Retatrutide analysis reports improvements in cardiovascular risk biomarkers
A post hoc analysis of Phase 2 trials found reductions in atherogenic lipoproteins and inflammatory biomarkers. The findings are encouraging, but biomarker changes do not establish cardiovascular outcomes.
View the PubMed recordSponsor-reported results
Lilly reports topline results from TRIUMPH-2 and TRIUMPH-3
Lilly announced Phase 3 topline results from two trials and said detailed results would be presented and published later. Retatrutide remains investigational.
Read the Lilly announcementResearch programme
Retatrutide research featured in Lilly's ADA 2026 programme
Lilly outlined Phase 3 retatrutide presentations planned for the American Diabetes Association's 2026 Scientific Sessions. This is sponsor-reported information, not regulatory approval.
Read the Lilly announcementSponsor-reported results
Lilly reports positive topline results from the TRIUMPH-1 Phase 3 trial
Lilly reported an average body-weight reduction of 28.3% at 80 weeks in the highest studied group. These are sponsor-reported topline findings; retatrutide remains investigational.
Read the Lilly announcementPeer-reviewed trial
Phase 2 obesity trial reported substantial weight reduction at 48 weeks
The peer-reviewed trial reported a 24.2% mean reduction at 48 weeks in the highest studied group, compared with 2.1% for placebo. Gastrointestinal adverse events were the most common and were dose-related.
View the peer-reviewed abstractPeer-reviewed trial
Phase 2 trial found meaningful glycaemic and body-weight changes
In adults with type 2 diabetes, the trial reported clinically meaningful improvements in glycaemic control and robust body-weight reductions, helping inform the Phase 3 programme.
View the peer-reviewed abstract